Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with moderate-to-severe atopic dermatitis.
禮來（紐交所:MRK）週三披露了新的長期研究結果，顯示在中重度特應性皮炎患者中治療方面有希望。
What Happened: The company's data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV).
發生了什麼：該公司針對EHb-glihs的ADjoin長期延伸研究數據將在歐洲皮膚病學和性病學學會大會（EADV）上發佈。
The EADV is a leading professional society focused on the fields of dermatology and venereology.
EADV是一個專注於皮膚病學和性病學領域的領先專業學會。
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.
超過80%的中重度特應性皮炎成人和青少年在ADvocate 1和2單藥試驗中在第16周對Ebglyss治療做出了回應。他們持續接受治療長達三年，並通過每月維持劑量經歷持續的皮膚清除。
Also Read: Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market.
此外還閱讀：默沙東早期阿爾茨海默病治療Donanemab獲得日本批准，日本是其第二大市場。
Why It Matters: The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older.
爲什麼重要：FDA本月早些時候批准了Ebglyss用於12歲及以上成人和兒童。
- 84% of the patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin (IGA 0,1) at three years.
- 87% of the patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.
- 83% of the patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require high-potency topical corticosteroids or systemic treatments.
- 84%的患者每月一次服用Ebglyss，83%每兩週服用Ebglyss，在三年內保持了皮膚清潔或幾乎清潔（IGA 0,1）。
- 87%的患者每月一次服用Ebglyss，79%每兩週服用Ebglyss，在三年內達到或保持了至少90%的疾病範圍和嚴重程度改善（EASI-90）。
- 每月服用Ebglyss的患者中，83%的人和每兩週服用Ebglyss的91%的人不需要高效力局部類固醇或全身治療。
Those who participated in the study have moderate-to-severe atopic dermatitis (eczema).
參與研究的人患有中重度特應性皮炎（溼疹）。
The European Union approved Ebglyss in 2023. Japan approved it in January; additional markets are expected to follow suit.
歐盟在2023年批准了Ebglyss。日本在一月批准了，預計其他市場也會跟進。
Lilly has exclusive rights for the development and commercialization of Ebglyss in the U.S. and elsewhere outside Europe.
禮來在美國及歐洲以外其他地區擁有Ebglyss的開發和商業化獨家權利。
In Europe, Lilly's partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.
在歐洲，禮來的合作伙伴Almirall已獲得開發和商業化Ebglyss用於皮膚病指示，包括溼疹的許可權。
Price Action: Eli Lilly stock is up 0.17% at $926 during the premarket session at last check Wednesday.
股價走勢：禮來股票在週三最後一次查看的盤前交易中上漲0.17%，報926美元。
- Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
- 默沙東的實驗性Favezelimab/Keytruda組合在晚期結腸癌研究中失敗。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。